Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
39.91 USD | -0.35% | +9.30% | -21.25% |
May. 31 | Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema | MT |
May. 31 | Transcript : Ionis Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.25% | 5.84B | |
+55.73% | 55.7B | |
+41.08% | 39.91B | |
-5.44% | 39.57B | |
-5.56% | 28.16B | |
+16.36% | 26.3B | |
-20.59% | 18.94B | |
+33.13% | 12.17B | |
+25.87% | 12.12B | |
+2.67% | 12.12B |
- Stock Market
- Equities
- IONS Stock
- News Ionis Pharmaceuticals, Inc.
- Citigroup Upgrades Ionis Pharmaceuticals to Neutral From Sell, Raises Price Target to $36 From $30